Impact of age on cardiovascular drug use in patients with chronic kidney disease - Université de Lorraine Access content directly
Journal Articles Clinical Kidney Journal Year : 2020

Impact of age on cardiovascular drug use in patients with chronic kidney disease


Background: Elderly patients with chronic kidney disease (CKD) are often excluded from clinical trials; this may affect their use of essential drugs for cardiovascular complications. We sought to assess the impact of age on cardiovascular drug use in elderly patients with CKD. Methods: We used baseline data from the Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort including 3033 adult patients with CKD Stages 3 and 4. We studied the use of recommended drugs for coronary artery disease (CAD), stroke and atrial fibrillation by age, after adjusting for socio-demographic and clinical conditions. Results: The patients' mean age was 66.8 years (mean estimated glomerular filtration rate 32.9 mL/min/1.73 m2). The prevalence of CAD was 24.5% [81.3% receiving antiplatelet agents, 75.6% renin-angiotensin system (RAS) blockers, 65.4% β-blockers and 81.3% lipid-lowering therapy], that of stroke 10.0% (88.8% receiving antithrombotic drugs) and that of atrial fibrillation 11.1% (69.5% receiving oral anticoagulants). Compared with patients aged <65 years, older age (≥65 years) was associated with greater use of antithrombotic drugs in stroke [adjusted odds ratio (aOR) (95% confidence interval) = 2.83 (1.04-7.73) for patients aged (75-84 years)] and less use of RAS blockers [aOR = 0.39 (0.16-0.89) for patients aged ≥85 years], β-blockers [aOR = 0.31 (0.19-0.53) for patients aged 75-84 years] and lipid-lowering therapy [aOR = 0.39 (0.15-1.02) for patients aged ≥85 years, P for trend = 0.01] in CAD. Older age was not associated with less use of antiplatelet agents in CAD or oral anticoagulants in atrial fibrillation. Conclusions: In patients with CKD, older age per se was not associated with the underuse of antithrombotic drugs but was for other major drugs, with a potential impact on cardiovascular outcomes.
Fichier principal
Vignette du fichier
sfz063.pdf (452.54 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Licence : CC BY NC - Attribution - NonCommercial

Dates and versions

hal-02572053 , version 1 (07-06-2023)


Attribution - NonCommercial



Cédric Villain, Sophie Liabeuf, Marie Metzger, Christian Combe, Denis Fouque, et al.. Impact of age on cardiovascular drug use in patients with chronic kidney disease. Clinical Kidney Journal, 2020, 13 (2), pp.199-207. ⟨10.1093/ckj/sfz063⟩. ⟨hal-02572053⟩
98 View
24 Download



Gmail Facebook X LinkedIn More